Helicobacter pylori activation of PARP-1 usurping a versatile regulator of host cellular health

Gut Microbes

Volumn 1, Issue 6, 2010, Pages

  Nossa, Carlos W ^a,b,c   Blanke, Steven R ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b University of Houston   (United States)

^c RICE UNIVERSITY   (United States)

Author keywords

Activation; Apoptosis; Cancer; Helicobacter pylori; Inflammation; PARP 1

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; VIRULENCE FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; DRUG TARGETING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMEOSTASIS; HOST CELL; HUMAN; INFLAMMATION; NONHUMAN; OVARY CANCER; PATHOGENESIS; PROTEIN FUNCTION; STOMACH CANCER; STOMACH DISEASE; VIRULENCE; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; REVIEW;

HELICOBACTER PYLORI;

ANIMALS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST-PATHOGEN INTERACTIONS; HUMANS; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79251527210     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.6.13572     Document Type: Article

References (89)

1. Blanke SR. Portals and pathways: Principles of bacterial toxin entry into cells. Microbe 2006; 1:26-32.
2. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009; 119:2475-87.
3. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10:403-14.
4. Nossa CW, Jain P, Tamilselvam B, Gupta VR, Chen LF, Schreiber V, et al. Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori. Proc Natl Acad Sci USA 2009; 106:19998-20003.
5. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26:882-93.
6. Hakme A, Wong HK, Dantzer F, Schreiber V. The expanding field of poly(ADP-ribosyl)ation reactions. 'Protein Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep 2008; 9:1094-100.
7. de Murcia G, Schreiber V, Molinete M, Saulier B, Poch O, Masson M, et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 1994; 138:15-24.
8. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005; 4:421-40.
9. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-28.
10. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R, et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 2007; 25:297-308.
11. Griesenbeck J, Ziegler M, Tomilin N, Schweiger M, Oei SL. Stimulation of the catalytic activity of poly(ADP-ribosyl) transferase by transcription factor Yin Yang 1. FEBS Lett 1999; 443:20-4.
12. Kun E, Kirsten E, Mendeleyev J, Ordahl CP. Regulation of the enzymatic catalysis of poly(ADPribose) polymerase by dsDNA, polyamines, Mg2+, Ca2+, histones H1 and H3 and ATP. Biochemistry 2004; 43:210-6.
13. Kirkland JB. Poly ADP-ribose polymerase-1 and health. Exp Biol Med (Maywood) 2010; 235:561-8.
14. Nossa CW, Blanke SR. Modification of a mammalian cell protein in the presence of [32P-adenylate] NAD: evidence for ADP ribosylation activity associated with Helicobacter pylori. Infect Immun 2006; 74:3071-6.
15. Maeda S, Omata M. Inflammation and cancer: role of nuclear factorkappaB activation. Cancer Sci 2008; 99:836-42.
16. Crabtree JE, Lindley IJ. Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease. Eur J Gastroenterol Hepatol 1994; 6:33-8.
17. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994; 29:425-9.
18. Crabtree JE, Xiang Z, Lindley IJ, Tompkins DS, Rappuoli R, Covacci A. Induction of interleukin-8 secretion from gastric epithelial cells by a cagA negative isogenic mutant of Helicobacter pylori. J Clin Pathol 1995; 48:967-9.
19. Crowe SE, Alvarez L, Dytoc M, Hunt RH, Muller M, Sherman P, et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995; 108:65-74.
20. Ding SZ, O'Hara AM, Denning TL, Dirden-Kramer B, Mifflin RC, Reyes VE, et al. Helicobacter pylori and H2O2 increase AP endonuclease-1/redox factor-1 expression in human gastric epithelial cells. Gastroenterology 2004; 127:845-58.
21. Wilcox CM, Harris PR, Redman TK, Kawabata S, Hiroi T, Kiyono H, et al. High mucosal levels of tumor necrosis factor alpha messenger RNA in AIDS-associated cytomegalovirus-induced esophagitis. Gastroenterology 1998; 114:77-82.
22. Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol Suppl 1988; 142:44-9.
23. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. Ann Intern Med 1988; 109:11-7.
24. Beswick EJ, Pinchuk IV, Das S, Powell DW, Reyes VE. Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells. Infect Immun 2007; 75:4334-41.
25. Enarsson K, Lundgren A, Kindlund B, Hermansson M, Roncador G, Banham AH, et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 2006; 121:358-68.
26. Harris PR, Wright SW, Serrano C, Riera F, Duarte I, Torres J, et al. Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology 2008; 134:491-9.
27. Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, Edebo A, et al. Mucosal FOXP3- expressing CD4+ CD25 high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005; 73:523-31.
28. Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 2006; 131:525-37.
29. Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, Das S, et al. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 2009; 199:494-504.
30. Fan X, Crowe SE, Behar S, Gunasena H, Ye G, Haeberle H, et al. The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage. J Exp Med 1998; 187:1659-69.
31. Jones NL, Shannon PT, Cutz E, Yeger H, Sherman PM. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection. Am J Pathol 1997; 151:1695-703.
32. Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang XJ, Ruiz B, et al. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res 1996; 56:3238-43.
33. Moss SF, Calam J, Agarwal B, Wang S, Holt PR. Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996; 38:498-501.
34. Wagner S, Beil W, Westermann J, Logan RP, Bock CT, Trautwein C, et al. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis. Gastroenterology 1997; 113:1836-47.
35. Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 2006; 70:789-829.
36. Hauser B, Groger M, Ehrmann U, Albicini M, Bruckner UB, Schelzig H, et al. The Parp-1 inhibitor INO-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock 2006; 25:633-40.
37. Black JH, Casey PJ, Albadawi H, Cambria RP, Watkins MT. Poly adenosine diphosphate-ribose polymerase inhibitor PJ34 abolishes systemic proinflammatory responses to thoracic aortic ischemia and reperfusion. J Am Coll Surg 2006; 203:44-53.
38. Pacher P, Liaudet L, Mabley JG, Cziraki A, Hasko G, Szabo C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 2006; 17:369-75.
39. Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 2009; 83:501-10.
40. Gonzalez-Rey E, Martinez-Romero R, O'Valle F, Aguilar-Quesada R, Conde C, Delgado M, et al. Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. PLoS One 2007; 2:1071.
41. Szabo C, Virag L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP, et al. Protection against peroxynitrite- induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 1998; 95:3867-72.
42. von Lukowicz T, Hassa PO, Lohmann C, Boren J, Braunersreuther V, Mach F, et al. PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res 2008; 78:158-66.
43. Czapski GA, Cakala M, Gajkowska B, Strosznajder JB. Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem Int 2006; 49:751-5.
44. Szabo C, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med 1997; 186:1041-9.
45. Hauschildt S, Scheipers P, Bessler W, Schwarz K, Ullmer A, Flad HD, et al. Role of ADP-ribosylation in activated monocytes/macrophages. Adv Exp Med Biol 1997; 419:249-52.
46. Giansanti V, Dona F, Tillhon M, Scovassi AI. PARP inhibitors: New tools to protect from inflammation. Biochem Pharmacol 2010; Epub ahead of print.
47. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006; 130:188-206.
48. Scovassi AI, Poirier GG. Poly(ADP-ribosylation) and apoptosis. Mol Cell Biochem 1999; 199:125-37.
49. Haddad M, Rhinn H, Bloquel C, Coqueran B, Szabo C, Plotkine M, et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol 2006; 149:23-30.
50. Huang D, Yang CZ, Yao L, Wang Y, Liao YH, Huang K. Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNFalpha and IL-6 expression in patients with unstable angina. Arch Med Res 2008; 39:775-84.
51. Naura AS, Datta R, Hans CP, Zerfaoui M, Rezk BM, Errami Y, et al. Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur Respir J 2009; 33:252-62.
52. Beneke S. Poly(ADP-ribose) polymerase activity in different pathologies-the link to inflammation and infarction. Exp Gerontol 2008; 43:605-14.
53. Hassa PO, Buerki C, Lombardi C, Imhof R, Hottiger MO. Transcriptional coactivation of nuclear factorkappaB- dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem 2003; 278:45145-53.
54. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NFkappaB-dependent transcription. J Biol Chem 2005; 280:40450-64.
55. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci 2009; 14:1116-28.
56. Wang Y, Dawson VL, Dawson TM. Poly(ADPribose) signals to mitochondrial AIF: A key event in parthanatos. Exp Neurol 2009.
57. Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann NY Acad Sci 2008; 1147:233-41.
58. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADPribose) polymerase-1-dependent cell death by apoptosis- inducing factor. Science 2002; 297:259-63.
59. Ruchalski K, Mao H, Singh SK, Wang Y, Mosser DD, Li F, et al. HSP72 inhibits apoptosis-inducing factor release in ATP-depleted renal epithelial cells. Am J Physiol Cell Physiol 2003; 285:1483-93.
60. Gagne JP, Isabelle M, Lo KS, Bourassa S, Hendzel MJ, Dawson VL, et al. Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADPribose)- associated protein complexes. Nucleic Acids Res 2008; 36:6959-76.
61. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA 2006; 103:18308-13.
62. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006; 103:18314-9.
63. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397:441-6.
64. Cheung EC, Joza N, Steenaart NA, McClellan KA, Neuspiel M, McNamara S, et al. Dissociating the dual roles of apoptosis-inducing factor in maintaining mitochondrial structure and apoptosis. EMBO J 2006; 25:4061-73.
65. Modjtahedi N, Giordanetto F, Madeo F, Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol 2006; 16:264-72.
66. Ashktorab H, Dashwood RH, Dashwood MM, Zaidi SI, Hewitt SM, Green WR, et al. H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria. Helicobacter 2008; 13:506-17.
67. Singh M, Prasad KN, Saxena A, Yachha SK. Helicobacter pylori induces apoptosis of T- and B-cell lines and translocates mitochondrial apoptosisinducing factor to nucleus. Curr Microbiol 2006; 52:254-60.
68. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30:58-63.
69. Kang X, Kim HJ, Ramirez M, Salameh S, Ma X. The septic shock-associated IL-10-1082 A > G polymorphism mediates allele-specific transcription via poly(ADP-Ribose) polymerase 1 in macrophages engulfing apoptotic cells. J Immunol 2010; 184:3718-24.
70. Altmeyer M, Barthel M, Eberhard M, Rehrauer H, Hardt WD, Hottiger MO. Absence of PARP1 delays the onset of Salmonella-induced gut inflammation. Infect Immun 2010; 78:3420-31.
71. Gaken JA, Tavassoli M, Gan SU, Vallian S, Giddings I, Darling DC, et al. Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity. J Virol 1996; 70:3992-4000.
72. Ha HC, Juluri K, Zhou Y, Leung S, Hermankova M, Snyder SH. Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration. Proc Natl Acad Sci USA 2001; 98:3364-8.
73. Nargi-Aizenman JL, Simbulan-Rosenthal CM, Kelly TA, Smulson ME, Griffin DE. Rapid activation of poly(ADP-ribose) polymerase contributes to Sindbis virus and staurosporine-induced apoptotic cell death. Virology 2002; 293:164-71.
74. Tempera I, Deng Z, Atanasiu C, Chen CJ, D'Erme M, Lieberman PM. Regulation of Epstein-Barr virus OriP replication by poly(ADP-ribose) polymerase 1. J Virol 84:4988-97.
75. Gordon-Shaag A, Yosef Y, Abd El-Latif M, Oppenheim A. The abundant nuclear enzyme PARP participates in the life cycle of simian virus 40 and is stimulated by minor capsid protein VP3. J Virol 2003; 77:4273-82.
76. Carbone M, Reale A, Di Sauro A, Sthandier O, Garcia MI, Maione R, et al. PARP-1 interaction with VP1 capsid protein regulates polyomavirus early gene expression(dagger). J Mol Biol 2006; 363:773-85.
77. Park E, Griffin DE. Interaction of Sindbis virus non-structural protein 3 with poly(ADP-ribose) polymerase 1 in neuronal cells. J Gen Virol 2009; 90:2073-80.
78. Zhou J, Huang JD, Poon VK, Chen DQ, Chan CC, Ng F, et al. Functional dissection of an IFNalpha/ beta receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. J Hepatol 2009; 51:322-32.
79. Muthumani K, Choo AY, Zong WX, Madesh M, Hwang DS, Premkumar A, et al. The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol 2006; 8:170-9.
80. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009; 12:153-6.
81. Toller IM, Altmeyer M, Kohler E, Hottiger MO, Muller A. Inhibition of ADP ribosylation prevents and cures Helicobacter-induced gastric preneoplasia. Cancer Res 2010; 70:5912-22.
82. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12:32-8.
83. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 2009; 18:31-43.
84. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008; 8:363-9.
85. Kinsella TJ. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 2009; 15:1853-9.
86. Boss DS, Beijnen JH, Schellens JH. Inducing Synthetic Lethality using PARP Inhibitors. Curr Clin Pharmacol 2010; 5:192-5.
87. Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 16:48-52.
88. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005; 7:60.
89. Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. Breast 2008; 17:441-50.